Xue DD, Zhang X, Li DW, Yang YL, Liu JJ. Protective effect of liraglutide on the myocardium of type 2 diabetic rats by inhibiting polyadenosine diphosphate-ribose polymerase-1. World J Diabetes 2023; 14(2): 110-119 [PMID: 36926657 DOI: 10.4239/wjd.v14.i2.110]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Feb 15, 2023; 14(2): 110-119 Published online Feb 15, 2023. doi: 10.4239/wjd.v14.i2.110
Protective effect of liraglutide on the myocardium of type 2 diabetic rats by inhibiting polyadenosine diphosphate-ribose polymerase-1
Dong-Dong Xue, Xiang Zhang, De-Wei Li, Yan-Lan Yang, Jing-Jin Liu
Dong-Dong Xue, Xiang Zhang, Jing-Jin Liu, Department of Endocrinology, Shanxi Provincial People's Hospital, Taiyuan 030000, Shanxi Province, China
De-Wei Li, Department of Thyroid Surgery, Shanxi Provincial People's Hospital, Taiyuan 030000, Shanxi Province, China
Yan-Lan Yang, Department of Endocrine, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China
Author contributions: Xue DD and Zhang X contributed to the methodology; Yang YL and Liu JJ contributed to the writing original draft preparation; Li DW, Liu JJ contributed to the revising.
Supported byShanxi Provincial Natural Science Foundation, No. 201701D121159; Shanxi Provincial Health and Family Planning Commission, No. 2014016; and Health Commission of Shanxi Province, No. 2019020.
Institutional animal care and use committee statement: All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals, protocol No. SYXK (Jin) 2018-1203, Animal Ethics Committee of Shanxi Provincial People's Hospital.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: The data to support the findings in the study are available from the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: September 16, 2022 Peer-review started: September 16, 2022 First decision: November 18, 2022 Revised: November 26, 2022 Accepted: December 21, 2022 Article in press: December 21, 2022 Published online: February 15, 2023 Processing time: 151 Days and 9.9 Hours
ARTICLE HIGHLIGHTS
Research background
Glucagon-like peptide-1 (GLP-1) can reduce the apoptosis of islet microcirculation endothelial cells and protect islet tissue through the polyadenosine diphosphate-ribose polymerase-1 (PARP-1)/iNOs pathway.
Research motivation
Whether GLP-1 can protect cardiomyocytes by inhibiting the expression of PARP-1 is still unclear.
Research objectives
This study investigated the mechanism of liraglutide in improving myocardial injury in type 2 diabetic rats, further clarified the protective effect of liraglutide on the heart, and provided a new option for the treatment of diabetic cardiomyopathy (DCM).
Research methods
After successful modeling, the rats were fed a high-glucose and high-fat diet for 8 wk and then started drug intervention. Blood samples were collected from the abdominal aorta to detect fasting blood glucose and lipid profiles. Intact heart tissue was dissected, and its weight was used to calculate the heart weight index. Hematoxylin and eosin staining was used to observe the pathological changes in the myocardium and the expression of PARP-1 in the heart by immunohistochemistry.
Research results
After liraglutide intervention, compared with the model group, the expression of PARP-1 in myocardial tissue was decreased, and the reduction was more obvious in the high-dose group (P < 0.05) but still higher than that in the normal control group.
Research conclusions
Liraglutide may improve myocardial injury in type 2 diabetic rats by inhibiting the expression of myocardial PARP-1 in a dose-dependent manner.
Research perspectives
Through the detection of heart weight index, blood lipids, and PARP-1 expression and observation of cardiac pathological changes in this experiment, we found that liraglutide can delay the occurrence and development of DCM by reducing the expression of cardiac PARP-1, which provides evidence for its clinical application in DCM.
